

Geoffrey J Lindeman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2100994/publications.pdf>

Version: 2024-02-01

181
papers

21,141
citations

20036

63
h-index

11282

141
g-index

184
all docs

184
docs citations

184
times ranked

28807
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>In vivo</i> genome editing screen identifies tumor suppressor genes that cooperate with Trp53 loss during mammary tumorigenesis. <i>Molecular Oncology</i> , 2022, 16, 1119-1131.	2.1	6
2	PALVEN: phase Ib trial of palbociclib, letrozole and venetoclax in estrogen receptor- and BCL2-positive advanced breast cancer. <i>Future Oncology</i> , 2022, 18, 1805-1816.	1.1	10
3	R code and downstream analysis objects for the scRNA-seq atlas of normal and tumorigenic human breast tissue. <i>Scientific Data</i> , 2022, 9, 96.	2.4	4
4	VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors – Efficacy, Safety, and Biomarker Results. <i>Clinical Cancer Research</i> , 2022, 28, 3256-3267.	3.2	28
5	Intravital microscopy of dynamic single-cell behavior in mouse mammary tissue. <i>Nature Protocols</i> , 2021, 16, 1907-1935.	5.5	28
6	Preclinical small molecule WEHI-7326 overcomes drug resistance and elicits response in patient-derived xenograft models of human treatment-refractory tumors. <i>Cell Death and Disease</i> , 2021, 12, 268.	2.7	2
7	A single-cell RNA expression atlas of normal, preneoplastic and tumorigenic states in the human breast. <i>EMBO Journal</i> , 2021, 40, e107333.	3.5	170
8	Results from VERONICA: A randomized, phase II study of second-/third-line venetoclax (VEN) + fulvestrant (F) versus F alone in estrogen receptor (ER)-positive, HER2-negative, locally advanced, or metastatic breast cancer (LA/MBC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 1004-1004.	0.8	28
9	Single cell transcriptome atlas of mouse mammary epithelial cells across development. <i>Breast Cancer Research</i> , 2021, 23, 69.	2.2	26
10	A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study. <i>Lancet Oncology</i> , The, 2021, 22, 1618-1631.	5.1	48
11	Universal genetic testing of patients with newly diagnosed breast cancer – ready for prime time?. <i>Medical Journal of Australia</i> , 2021, 215, 449-453.	0.8	1
12	Mammary tumour cells remodel the bone marrow vascular microenvironment to support metastasis. <i>Nature Communications</i> , 2021, 12, 6920.	5.8	32
13	Stem Cells and the Differentiation Hierarchy in Mammary Gland Development. <i>Physiological Reviews</i> , 2020, 100, 489-523.	13.1	144
14	Modeling Breast Cancer Using CRISPR-Cas9-Mediated Engineering of Human Breast Organoids. <i>Journal of the National Cancer Institute</i> , 2020, 112, 540-544.	3.0	104
15	Outcomes of women at high familial risk for breast cancer: An 8-year single-center experience. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, e27-e37.	0.7	1
16	Preferences for breast cancer prevention among women with a BRCA1 or BRCA2 mutation. <i>Hereditary Cancer in Clinical Practice</i> , 2020, 18, 20.	0.6	3
17	Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells. <i>Nature Communications</i> , 2020, 11, 6335.	5.8	46
18	Predictors of long-term cancer-related distress among female BRCA1 and BRCA2 mutation carriers without a cancer diagnosis: an international analysis. <i>British Journal of Cancer</i> , 2020, 123, 268-274.	2.9	20

#	ARTICLE	IF	CITATIONS
19	Targeting triple-negative breast cancers with the Smac-mimetic birinapant. <i>Cell Death and Differentiation</i> , 2020, 27, 2768-2780.	5.0	31
20	Tissue-resident ductal macrophages survey the mammary epithelium and facilitate tissue remodelling. <i>Nature Cell Biology</i> , 2020, 22, 546-558.	4.6	118
21	Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4120-4134.	3.2	65
22	Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. <i>European Urology</i> , 2019, 76, 831-842.	0.9	148
23	Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer. <i>Nature Communications</i> , 2019, 10, 397.	5.8	59
24	Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 383-393.	1.1	12
25	Experiences and interpretations of BRCA1/2 testing among women affected by breast or ovarian cancer who received a negative result. <i>Journal of Community Genetics</i> , 2019, 10, 501-514.	0.5	3
26	Intraclonal Plasticity in Mammary Tumors Revealed through Large-Scale Single-Cell Resolution 3D Imaging. <i>Cancer Cell</i> , 2019, 35, 618-632.e6.	7.7	119
27	Barcoding reveals complex clonal behavior in patient-derived xenografts of metastatic triple negative breast cancer. <i>Nature Communications</i> , 2019, 10, 766.	5.8	99
28	A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast Cancer. <i>Cancer Discovery</i> , 2019, 9, 354-369.	7.7	104
29	Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer. <i>British Journal of Cancer</i> , 2019, 120, 279-285.	2.9	17
30	Randomized phase II trial of venetoclax + fulvestrant versus fulvestrant in estrogen receptor+, HER2- locally advanced or metastatic breast cancer following recurrence or progression during or after a CDK4/6 inhibitor: VERONICA. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS1108-TPS1108.	0.8	2
31	Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. <i>British Journal of Cancer</i> , 2018, 118, 266-276.	2.9	12
32	Foxp1 Is Indispensable for Ductal Morphogenesis and Controls the Exit of Mammary Stem Cells from Quiescence. <i>Developmental Cell</i> , 2018, 47, 629-644.e8.	3.1	24
33	Canonical PRC2 function is essential for mammary gland development and affects chromatin compaction in mammary organoids. <i>PLoS Biology</i> , 2018, 16, e2004986.	2.6	10
34	Spotlight on the utility of the Oncotype DX [®] breast cancer assay. <i>International Journal of Women's Health</i> , 2018, Volume 10, 89-100.	1.1	57
35	Frequent activating STAT3 mutations and novel recurrent genomic abnormalities detected in breast implant-associated anaplastic large cell lymphoma. <i>Oncotarget</i> , 2018, 9, 36126-36136.	0.8	62
36	Derivation of a robust mouse mammary organoid system for studying tissue dynamics. <i>Development (Cambridge)</i> , 2017, 144, 1065-1071.	1.2	78

#	ARTICLE	IF	CITATIONS
37	Solitary pituitary metastasis from <scp>HER2</scp>-positive breast cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, e181-e184.	0.7	16
38	Out-RANKing BRCA1 in Mutation Carriers. <i>Cancer Research</i> , 2017, 77, 595-600.	0.4	33
39	Patient and medical barriers preclude uptake of tamoxifen preventative therapy in women with a strong family history. <i>Breast</i> , 2017, 32, 93-97.	0.9	8
40	Mainstreaming cancer genetics: A model integrating germline BRCA testing into routine ovarian cancer clinics. <i>Gynecologic Oncology</i> , 2017, 145, 130-136.	0.6	91
41	Identification of quiescent and spatially restricted mammary stem cells that are hormone responsive. <i>Nature Cell Biology</i> , 2017, 19, 164-176.	4.6	99
42	RE: Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	11
43	Combined immune checkpoint blockade as a therapeutic strategy for <i>BRCA1</i>-mutated breast cancer. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	227
44	New Monoclonal Antibodies to Defined Cell Surface Proteins on Human Pluripotent Stem Cells. <i>Stem Cells</i> , 2017, 35, 626-640.	1.4	18
45	Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	148
46	Construction of developmental lineage relationships in the mouse mammary gland by single-cell RNA profiling. <i>Nature Communications</i> , 2017, 8, 1627.	5.8	151
47	Preferences for breast cancer risk reduction among BRCA1/BRCA2 mutation carriers: a discrete-choice experiment. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 433-444.	1.1	31
48	Patient-derived xenograft (PDX) models in basic and translational breast cancer research. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 547-573.	2.7	189
49	The complexities and caveats of lineage tracing in the mammary gland. <i>Breast Cancer Research</i> , 2016, 18, 116.	2.2	25
50	Essential role for a novel population of binucleated mammary epithelial cells in lactation. <i>Nature Communications</i> , 2016, 7, 11400.	5.8	80
51	RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers. <i>Nature Medicine</i> , 2016, 22, 933-939.	15.2	224
52	Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer. <i>Oncogene</i> , 2016, 35, 1877-1887.	2.6	116
53	Patient-derived xenograft models of breast cancer and their predictive power. <i>Breast Cancer Research</i> , 2015, 17, 17.	2.2	225
54	Large genomic rearrangements in the familial breast and ovarian cancer gene BRCA1 are associated with an increased frequency of high risk features. <i>Familial Cancer</i> , 2015, 14, 287-295.	0.9	22

#	ARTICLE	IF	CITATIONS
55	A pooled shRNA screen for regulators of primary mammary stem and progenitor cells identifies roles for Asap1 and Prox1. <i>BMC Cancer</i> , 2015, 15, 221.	1.1	31
56	EGF-mediated induction of Mcl-1 at the switch to lactation is essential for alveolar cell survival. <i>Nature Cell Biology</i> , 2015, 17, 365-375.	4.6	65
57	Integration of microRNA signatures of distinct mammary epithelial cell types with their gene expression and epigenetic portraits. <i>Breast Cancer Research</i> , 2015, 17, 85.	2.2	29
58	Pro-apoptotic Bim suppresses breast tumor cell metastasis and is a target gene of SNAI2. <i>Oncogene</i> , 2015, 34, 3926-3934.	2.6	27
59	Breast cancer prevention for BRCA1 and BRCA2 mutation carriers: is there a role for tamoxifen?. <i>Future Oncology</i> , 2014, 10, 499-502.	1.1	15
60	Dual roles for Id4 in the regulation of estrogen signaling in the mammary gland and ovary. <i>Development (Cambridge)</i> , 2014, 141, 3159-3164.	1.2	30
61	In situ identification of bipotent stem cells in the mammary gland. <i>Nature</i> , 2014, 506, 322-327.	13.7	440
62	Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study. <i>European Urology</i> , 2014, 66, 489-499.	0.9	195
63	The Mammary Stem Cell Hierarchy. <i>Current Topics in Developmental Biology</i> , 2014, 107, 133-160.	1.0	49
64	Breast-Cancer Risk in Families with Mutations in <i>PALB2</i> . <i>New England Journal of Medicine</i> , 2014, 371, 497-506.	13.9	745
65	Distinct nuclear receptor expression in stroma adjacent to breast tumors. <i>Breast Cancer Research and Treatment</i> , 2013, 142, 211-223.	1.1	45
66	Tumour morphology predicts PALB2 germline mutation status. <i>British Journal of Cancer</i> , 2013, 109, 154-163.	2.9	19
67	Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer. <i>Breast Cancer Research</i> , 2013, 15, R88.	2.2	168
68	The incidence of PALB2 c.3113G>A in women with a strong family history of breast and ovarian cancer attending familial cancer centres in Australia. <i>Familial Cancer</i> , 2013, 12, 587-595.	0.9	11
69	Global Changes in the Mammary Epigenome Are Induced by Hormonal Cues and Coordinated by Ezh2. <i>Cell Reports</i> , 2013, 3, 411-426.	2.9	117
70	Targeting BCL-2 with the BH3 Mimetic ABT-199 in Estrogen Receptor-Positive Breast Cancer. <i>Cancer Cell</i> , 2013, 24, 120-129.	7.7	243
71	Targeting BCL-2 in breast cancer: exploiting a tumor lifeline to deliver a mortal blow?. <i>Breast Cancer Management</i> , 2013, 2, 1-4.	0.2	9
72	Role of Engrailed-2 (EN2) as a prostate cancer detection biomarker in genetically high risk men. <i>Scientific Reports</i> , 2013, 3, 2059.	1.6	26

#	ARTICLE	IF	CITATIONS
73	The Angelina Jolie effect. <i>Medical Journal of Australia</i> , 2013, 199, 646-646.	0.8	26
74	Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 2766-2771.	3.3	173
75	A Role for Common Genomic Variants in the Assessment of Familial Breast Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 4330-4336.	0.8	74
76	Isolation of Mouse Mammary Epithelial Subpopulations: A Comparison of Leading Methods. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2012, 17, 91-97.	1.0	65
77	Cancer Stem Cells: Current Status and Evolving Complexities. <i>Cell Stem Cell</i> , 2012, 10, 717-728.	5.2	1,128
78	Aldehyde Dehydrogenase Activity Is a Biomarker of Primitive Normal Human Mammary Luminal Cells. <i>Stem Cells</i> , 2012, 30, 344-348.	1.4	70
79	Triple-negative breast cancer: making the most of a misnomer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2012, 8, 145-155.	0.7	9
80	Analysis of RAD51C germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patients. <i>Human Mutation</i> , 2012, 33, 95-99.	1.1	64
81	The unmasking of novel unipotent stem cells in the mammary gland. <i>EMBO Journal</i> , 2011, 30, 4858-4859.	3.5	18
82	Cell fate takes a slug in BRCA1-associated breast cancer. <i>Breast Cancer Research</i> , 2011, 13, 306.	2.2	16
83	Jekyll or Hyde: does Matrigel provide a more or less physiological environment in mammary repopulating assays?. <i>Breast Cancer Research</i> , 2011, 13, 108.	2.2	50
84	Mammary stem cells and their regulation by steroid hormones. <i>Expert Review of Endocrinology and Metabolism</i> , 2011, 6, 371-381.	1.2	3
85	Targeted prostate cancer screening in men with mutations in <i>BRCA1</i> and <i>BRCA2</i> detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study. <i>BJU International</i> , 2011, 107, 28-39.	1.3	83
86	LMO4 expression in squamous cell carcinoma of the anterior tongue. <i>Histopathology</i> , 2011, 58, 477-480.	1.6	9
87	The role of poly adenosine diphosphate ribose polymerase inhibitors in breast and ovarian cancer: Current status and future directions. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2011, 7, 197-211.	0.7	13
88	Analysis of Brca1-deficient mouse mammary glands reveals reciprocal regulation of Brca1 and c-kit. <i>Oncogene</i> , 2011, 30, 1597-1607.	2.6	26
89	Hereditary Breast Cancer Genetics—From Clinical Curiosities to Mainstream Paradigms. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2011, 16, 1-2.	1.0	6
90	Proteomic profiling of secretome and adherent plasma membranes from distinct mammary epithelial cell subpopulations. <i>Proteomics</i> , 2011, 11, 4029-4039.	1.3	25

#	ARTICLE	IF	CITATIONS
91	Challenges to the Development of New Agents for Molecularly Defined Patient Subsets: Lessons From <i>BRCA1/2</i> -Associated Breast Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 4224-4226.	0.8	23
92	Gata-3 Negatively Regulates the Tumor-Initiating Capacity of Mammary Luminal Progenitor Cells and Targets the Putative Tumor Suppressor Caspase-14. <i>Molecular and Cellular Biology</i> , 2011, 31, 4609-4622.	1.1	96
93	An autocrine TGF- β 2/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition. <i>Molecular Biology of the Cell</i> , 2011, 22, 1686-1698.	0.9	505
94	Breast Conservation Versus Mastectomy in Triple-Negative Breast Cancer: Two Steps Forward, One Step Back?. <i>Journal of Clinical Oncology</i> , 2011, 29, 4722-4723.	0.8	4
95	Frequent somatic mutations of GATA3 in non- <i>BRCA1/BRCA2</i> familial breast tumors, but not in <i>BRCA1</i> -, <i>BRCA2</i> - or sporadic breast tumors. <i>Breast Cancer Research and Treatment</i> , 2010, 119, 491-496.	1.1	30
96	Loss of STARD10 expression identifies a group of poor prognosis breast cancers independent of HER2/Neu and triple negative status. <i>International Journal of Cancer</i> , 2010, 126, 1445-1453.	2.3	11
97	Insights into the cell of origin in breast cancer and breast cancer stem cells. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2010, 6, 89-97.	0.7	51
98	Control of mammary stem cell function by steroid hormone signalling. <i>Nature</i> , 2010, 465, 798-802.	13.7	617
99	The rs10993994 Risk Allele for Prostate Cancer Results in Clinically Relevant Changes in Microseminoprotein-Beta Expression in Tissue and Urine. <i>PLoS ONE</i> , 2010, 5, e13363.	1.1	73
100	Gene Methylation in Breast Ductal Fluid from <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 265-274.	1.1	26
101	Stem cells and cancer – The promise and puzzles. <i>Molecular Oncology</i> , 2010, 4, 369-372.	2.1	25
102	Transcriptome analyses of mouse and human mammary cell subpopulations reveal multiple conserved genes and pathways. <i>Breast Cancer Research</i> , 2010, 12, R21.	2.2	354
103	Impaired lactation in mice expressing dominant-negative FADD in mammary epithelium. <i>Developmental Dynamics</i> , 2009, 238, 1010-1016.	0.8	3
104	Lineage Enforcement by Inductive Mesenchyme on Adult Epithelial Stem Cells across Developmental Germ Layers. <i>Stem Cells</i> , 2009, 27, 3032-3042.	1.4	28
105	Aberrant luminal progenitors as the candidate target population for basal tumor development in <i>BRCA1</i> mutation carriers. <i>Nature Medicine</i> , 2009, 15, 907-913.	15.2	1,261
106	EpCAM and solid tumour fractionation. <i>Nature Reviews Cancer</i> , 2009, 9, 143-143.	12.8	5
107	Predictors of the use of complementary and alternative medicine (CAM) by women at high risk for breast cancer. <i>European Journal of Cancer</i> , 2009, 45, 551-560.	1.3	26
108	Expression of S100A2 Calcium-Binding Protein Predicts Response to Pancreatectomy for Pancreatic Cancer. <i>Gastroenterology</i> , 2009, 137, 558-568.e11.	0.6	82

#	ARTICLE	IF	CITATIONS
109	Resident macrophages influence stem cell activity in the mammary gland. <i>Breast Cancer Research</i> , 2009, 11, R62.	2.2	103
110	BARD1 variants are not associated with breast cancer risk in Australian familial breast cancer. <i>Breast Cancer Research and Treatment</i> , 2008, 111, 505-509.	1.1	23
111	Breast cancer risk and the BRCA1 interacting protein CTIP. <i>Breast Cancer Research and Treatment</i> , 2008, 112, 351-352.	1.1	3
112	Deaf-1 regulates epithelial cell proliferation and side-branching in the mammary gland. <i>BMC Developmental Biology</i> , 2008, 8, 94.	2.1	28
113	Expression of LMO4 and outcome in pancreatic ductal adenocarcinoma. <i>British Journal of Cancer</i> , 2008, 98, 537-541.	2.9	23
114	Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. <i>Nature Reviews Cancer</i> , 2008, 8, 755-768.	12.8	3,070
115	MACROPHAGES, MORE THAN JUST SCAVENGERS: THEIR ROLE IN BREAST DEVELOPMENT AND CANCER. <i>ANZ Journal of Surgery</i> , 2008, 78, 432-436.	0.3	8
116	The future of mammary stem cell biology: the power of in vivo transplants. <i>Breast Cancer Research</i> , 2008, 10, 402; author reply 403.	2.2	15
117	Grhl3 and Lmo4 play coordinate roles in epidermal migration. <i>Developmental Biology</i> , 2008, 321, 263-272.	0.9	42
118	Notch Signaling Regulates Mammary Stem Cell Function and Luminal Cell-Fate Commitment. <i>Cell Stem Cell</i> , 2008, 3, 429-441.	5.2	398
119	The beliefs, and reported and intended behaviors of unaffected men in response to their family history of prostate cancer. <i>Genetics in Medicine</i> , 2008, 10, 430-438.	1.1	9
120	The Mammary Progenitor Marker CD61/ β 3 Integrin Identifies Cancer Stem Cells in Mouse Models of Mammary Tumorigenesis. <i>Cancer Research</i> , 2008, 68, 7711-7717.	0.4	304
121	Cancer Risk Management Practices of Noncarriers Within BRCA1/2 Mutation "Positive Families in the Kathleen Cuninghame Foundation Consortium for Research Into Familial Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 225-232.	0.8	19
122	Towards more effective and equitable genetic testing for BRCA1 and BRCA2 mutation carriers. <i>Journal of Medical Genetics</i> , 2008, 45, 765-766.	1.5	1
123	The Ets transcription factor Elf5 specifies mammary alveolar cell fate. <i>Genes and Development</i> , 2008, 22, 581-586.	2.7	205
124	Delineating the Epithelial Hierarchy in the Mouse Mammary Gland. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , 2008, 73, 469-478.	2.0	40
125	Knocking Off SOCS Genes in the Mammary Gland. <i>Cell Cycle</i> , 2007, 6, 799-803.	1.3	42
126	Prostate screening uptake in Australian BRCA1 and BRCA2 carriers. <i>Hereditary Cancer in Clinical Practice</i> , 2007, 5, 161.	0.6	3

#	ARTICLE	IF	CITATIONS
127	Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. <i>Nature Cell Biology</i> , 2007, 9, 201-209.	4.6	717
128	The Molecular Culprits Underlying Precocious Mammary Gland Involution. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2007, 12, 15-23.	1.0	30
129	The Emerging Picture of the Mouse Mammary Stem Cell. <i>Stem Cell Reviews and Reports</i> , 2007, 3, 114-123.	5.6	36
130	Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource. <i>Breast Cancer Research</i> , 2006, 8, R12.	2.2	135
131	Mammary Stem Cells and Mammopoiesis: Figure 1.. <i>Cancer Research</i> , 2006, 66, 9798-9801.	0.4	69
132	CPAP interacts with 14-3-3 in a cell cycle-dependent manner. <i>Biochemical and Biophysical Research Communications</i> , 2006, 342, 1203-1210.	1.0	9
133	Genetic services for men: The preferences of men with a family history of prostate cancer. <i>Genetics in Medicine</i> , 2006, 8, 771-778.	1.1	9
134	Risk-reducing surgery, screening and chemoprevention practices of BRCA1 and BRCA2 mutation carriers: a prospective cohort study. <i>Clinical Genetics</i> , 2006, 70, 198-206.	1.0	67
135	Generation of a functional mammary gland from a single stem cell. <i>Nature</i> , 2006, 439, 84-88.	13.7	1,824
136	c-myc as a mediator of accelerated apoptosis and involution in mammary glands lacking Socs3. <i>EMBO Journal</i> , 2006, 25, 5805-5815.	3.5	48
137	Shedding Light on Mammary Stem Cells and Tumorigenesis. <i>Cell Cycle</i> , 2006, 5, 671-672.	1.3	2
138	Steroid Hormone Receptor Status of Mouse Mammary Stem Cells. <i>Journal of the National Cancer Institute</i> , 2006, 98, 1011-1014.	3.0	271
139	Socs2 and Elf5 Mediate Prolactin-Induced Mammary Gland Development. <i>Molecular Endocrinology</i> , 2006, 20, 1177-1187.	3.7	138
140	XIAP-deficiency leads to delayed lobuloalveolar development in the mammary gland. <i>Cell Death and Differentiation</i> , 2005, 12, 87-90.	5.0	58
141	Elf5 is essential for early embryogenesis and mammary gland development during pregnancy and lactation. <i>EMBO Journal</i> , 2005, 24, 635-644.	3.5	129
142	Loss of the LIM domain protein Lmo4 in the mammary gland during pregnancy impedes lobuloalveolar development. <i>Oncogene</i> , 2005, 24, 4820-4828.	2.6	25
143	Breast cancer protein StarD10 identified by three-dimensional separation using free-flow electrophoresis, reversed-phase high-performance liquid chromatography, and sodium dodecyl sulfate-polyacrylamide gel electrophoresis. <i>Electrophoresis</i> , 2005, 26, 1029-1037.	1.3	7
144	Predictors of participation in clinical and psychosocial follow-up of the kConFab breast cancer family cohort. <i>Familial Cancer</i> , 2005, 4, 105-113.	0.9	47

#	ARTICLE	IF	CITATIONS
145	Genetic, functional, and histopathological evaluation of two C-terminal BRCA1 missense variants. <i>Journal of Medical Genetics</i> , 2005, 43, 74-83.	1.5	39
146	StarD10, a START Domain Protein Overexpressed in Breast Cancer, Functions as a Phospholipid Transfer Protein. <i>Journal of Biological Chemistry</i> , 2005, 280, 27436-27442.	1.6	79
147	The LIM Domain Protein Lmo4 Is Highly Expressed in Proliferating Mouse Epithelial Tissues. <i>Journal of Histochemistry and Cytochemistry</i> , 2005, 53, 475-486.	1.3	39
148	Overexpression of LMO4 induces mammary hyperplasia, promotes cell invasion, and is a predictor of poor outcome in breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 7659-7664.	3.3	83
149	Mutation analysis of FANCD2, BRIP1/BACH1, LMO4 and SFN in familial breast cancer. <i>Breast Cancer Research</i> , 2005, 7, R1005-16.	2.2	44
150	Defective Neural Tube Closure and Anteroposterior Patterning in Mice Lacking the LIM Protein LMO4 or Its Interacting Partner Deaf-1. <i>Molecular and Cellular Biology</i> , 2004, 24, 2074-2082.	1.1	104
151	The Phosphoprotein StarD10 Is Overexpressed in Breast Cancer and Cooperates with ErbB Receptors in Cellular Transformation. <i>Cancer Research</i> , 2004, 64, 3538-3544.	0.4	37
152	Dimerization of CtIP, a BRCA1- and CtBP-interacting Protein, Is Mediated by an N-terminal Coiled-coil Motif. <i>Journal of Biological Chemistry</i> , 2004, 279, 26932-26938.	1.6	46
153	Differential hypermethylation of SOCS genes in ovarian and breast carcinomas. <i>Oncogene</i> , 2004, 23, 7726-7733.	2.6	200
154	Frequency of the ATM IVS10-6Tâ†’G variant in Australian multiple-case breast cancer families. <i>Breast Cancer Research</i> , 2004, 6, R401-7.	2.2	15
155	Accuracy and completeness in reporting family history of prostate cancer by unaffected men. <i>Urology</i> , 2004, 63, 1111-1116.	0.5	22
156	Complete radiological and metabolic response of metastatic renal cell carcinoma to SU5416 (semaxanib) in a patient with probable von Hippel-Lindau syndrome. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2004, 22, 193-196.	0.8	35
157	MMTV-trBrca1 mice display strain-dependent abnormalities in vaginal development. <i>International Journal of Developmental Biology</i> , 2004, 48, 675-678.	0.3	5
158	Identification of Taxreb107 as a lactogenic hormone responsive gene in mammary epithelial cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2003, 1642, 139-147.	1.9	1
159	Mutational analysis of theLMO4 gene, encoding a BRCA1-interacting protein, in breast carcinomas. <i>International Journal of Cancer</i> , 2003, 107, 155-158.	2.3	13
160	Bfk: a novel weakly proapoptotic member of the Bcl-2 protein family with a BH3 and a BH2 region. <i>Cell Death and Differentiation</i> , 2003, 10, 185-192.	5.0	45
161	Novelp53germline mutation in a patient with Liâˆ’Fraumeni syndrome. <i>Internal Medicine Journal</i> , 2003, 33, 621-623.	0.5	3
162	Two promoters within the human LMO4 gene contribute to its overexpression in breast cancer cells. <i>Genomics</i> , 2003, 82, 280-287.	1.3	13

#	ARTICLE	IF	CITATIONS
163	Transcriptional regulators in mammary gland development and cancer. <i>International Journal of Biochemistry and Cell Biology</i> , 2003, 35, 1034-1051.	1.2	46
164	Threonine 391 Phosphorylation of the Human Prolactin Receptor Mediates a Novel Interaction with 14-3-3 Proteins. <i>Journal of Biological Chemistry</i> , 2003, 278, 32929-32935.	1.6	24
165	Investigation of the Transcriptional Changes Underlying Functional Defects in the Mammary Glands of Prolactin Receptor Knockout Mice. <i>Endocrine Reviews</i> , 2003, 58, 297-323.	7.1	92
166	The LIM Domain Protein LMO4 Interacts with the Cofactor CtIP and the Tumor Suppressor BRCA1 and Inhibits BRCA1 Activity. <i>Journal of Biological Chemistry</i> , 2002, 277, 7849-7856.	1.6	135
167	CPAP Is a Novel Stat5-Interacting Cofactor that Augments Stat5-Mediated Transcriptional Activity. <i>Molecular Endocrinology</i> , 2002, 16, 2019-2033.	3.7	48
168	Germline BRCA1 promoter deletions in UK and Australian familial breast cancer patients: Identification of a novel deletion consistent with BRCA1:BRCA1 recombination. <i>Human Mutation</i> , 2002, 19, 435-442.	1.1	32
169	Familial Cancer 2003 – Research and Practice, Couran Cove, Queensland, Australia, 6 September 2003. <i>Familial Cancer</i> , 2002, 3, 75-77.	0.9	0
170	SOCS1 deficiency results in accelerated mammary gland development and rescues lactation in prolactin receptor-deficient mice. <i>Genes and Development</i> , 2001, 15, 1631-1636.	2.7	93
171	E2F4 Is Exported from the Nucleus in a CRM1-Dependent Manner. <i>Molecular and Cellular Biology</i> , 2001, 21, 1384-1392.	1.1	96
172	The LIM domain gene LMO4 inhibits differentiation of mammary epithelial cells in vitro and is overexpressed in breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 14452-14457.	3.3	124
173	The Proapoptotic BH3-Only Protein Bim Is Expressed in Hematopoietic, Epithelial, Neuronal, and Germ Cells. <i>American Journal of Pathology</i> , 2000, 157, 449-461.	1.9	214
174	E2F4 and E2F5 Play an Essential Role in Pocket Protein-Mediated G1 Control. <i>Molecular Cell</i> , 2000, 6, 729-735.	4.5	249
175	A specific, nonproliferative role for E2F-5 in choroid plexus function revealed by gene targeting. <i>Genes and Development</i> , 1998, 12, 1092-1098.	2.7	160
176	The subcellular localization of E2F-4 is cell-cycle dependent. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997, 94, 5095-5100.	3.3	183
177	Overexpressed max is not oncogenic and attenuates myc-induced lymphoproliferation and lymphomagenesis in transgenic mice. <i>Oncogene</i> , 1995, 10, 1013-7.	2.6	36
178	B-lymphoid to granulocytic switch during hematopoiesis in a transgenic mouse strain. <i>Immunity</i> , 1994, 1, 517-527.	6.6	28
179	INTRAVENOUS OR ORAL ADJUVANT CMF FOR NODE-POSITIVE BREAST CANCER. <i>ANZ Journal of Surgery</i> , 1992, 62, 556-562.	0.3	12
180	MANAGEMENT OF TESTICULAR SEMINOMA AT WESTMEAD HOSPITAL FROM 1980 to 87. <i>ANZ Journal of Surgery</i> , 1991, 61, 211-216.	0.3	5

#	ARTICLE	IF	CITATIONS
181	The Role of Bipedal Lymphangiography in Testicular Seminoma. Journal of Medical Imaging and Radiation Oncology, 1990, 34, 293-296.	0.6	5